# US 2013/0156756 A1 · Substituted Triazolopyridines

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0156756 A1
- Document ID: US20130156756A1
- Status: Published application
- Kind: A1
- Application number: 13/704,859
- Filed: 2011-06-14
- Published: 2013-06-20
- Earliest claimed: 2010-06-16
- Assignees: Bayer Intellectual Property GmbH
- Inventors: Volker Schulze; Dirk Kosemund; Hartmut Schirok; Benjamin Bader; Philip Lienau; Antje Margret Wengner; Hans Briem; Simon Holton; Gerhard Siemeister; Stefan Prechtl; Marcus Koppitz; Detlef Stöckigt; Olaf Prien
- Web page: https://patentgrep.com/patent/US20130156756A1

## CPC

- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/277: having a ring, e.g. verapamil
- A61K 31/282: Platinum compounds
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/427: not condensed and containing further heterocyclic rings
- A61K 31/428: condensed with carbocyclic rings
- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/541: Non-condensed thiazines containing further heterocyclic rings
- A61K 31/565: not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 31/69: Boron compounds
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 33/243: Platinum; Compounds thereof
- A61K 38/14: Peptides containing saccharide radicals; Derivatives thereof {, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin}
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 5/00: Drugs for disorders of the endocrine system
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/08: of the prostate
- A61P 13/10: of the bladder
- A61P 13/12: of the kidneys
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 19/00: Drugs for skeletal disorders
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 471/04: Ortho-condensed systems
- C07D 491/08: Bridged systems
- C07D 491/107: with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention relates to substituted triazolopyridine compounds of general formula (I): in which R1, R2, R3, R4, and R5 are as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease of uncontrolled cell growth, proliferation and/or survival as well as to the use of intermediate compounds for the preparation of said compounds.

## Claims

### Claim 1

A compound of general formula (I):
in which:
R1 represents an aryl or heteroaryl group
which is substituted, one or more times, identically or differently, with a substituent selected from:
R6—(C1-C6-alkyl)-, R6—(CH2)n(CHOH)(CH2)m—, R6—(C1-C6-alkoxy)-, R6—(CH2)n(CHOH)(CH2)p—O—, R6—(C1-C6-alkoxy-C1-C6-alkyl)-, R6—(C1-C6-alkoxy-C1-C6-alkyl)-O—, R6—O—, —C(═O)R6, —C(═O)O—R6, —OC(═O)—R6, —N(H)C(═O)R6, —N(R7)C(═O)R6, —N(H)C(═O)NR6R7, —N(R7)C(═O)NR6R7, —NR6R7, —C(═O)N(H)R6, —C(═O)NR6R7, R6—S—, R6—S(═O)—, R6—S(═O)2—, —N(H)S(═O)R6, —N(R7)S(═O)R6, —S(═O)N(H)R6, —S(═O)NR6R7, —N(H)S(═O)2R6, —N(R7)S(═O)2R6, —S(═O)2N(H)R6, —S(═O)2NR6R7, —S(═O)(═NR6)R7, —S(═O)(═NR7)R6, —N═S(═O)(R6)R7;
and
which is optionally substituted, one or more times, identically or differently, with a substituent Rxy selected from:
halo-, hydroxyl-, cyano-, nitro-, C1-C6-alkyl-, halo-C1-C6-alkyl-, C1-C6-alkoxy-, halo-C1-C6-alkoxy-, hydroxy-C1-C6-alkyl-, C1-C6-alkoxy-C1-C6-alkyl-, halo-C1-C6-alkoxy-C1-C6-alkyl-, R8—(C1-C6-alkyl)-, R8—(CH2)n(CHOH)(CH2)m—, R8—(C1-C6-alkoxy)-, R8—(CH2)n(CHOH)(CH2)p—O—, R8—(C1-C6-alkoxy-C1-C6-alkyl)-, R8—(C1-C6-alkoxy-C1-C6-alkyl)-O—, R8—O—, —C(═O)R8, —C(═O)O—R8, —OC(═O)—R8, —N(H)C(═O)R8, —N(R7)C(═O)R8, —N(H)C(═O)NR8R7, —N(R7)C(═O)NR8R7, —NR8R7, —C(═O)N(H)R8, —C(═O)NR8R7, R8—S—, R8—S(═O)—, R8—S(═O)2—, —N(H)S(═O)R8, —N(R7)S(═O)R8, —S(═O)N(H)R8, —S(═O)NR8R7, —N(H)S(═O)2R8, —N(R7)S(═O)2R8, —S(═O)2N(H)R8, —S(═O)2NR8R7, —S(═O)(═NR8)R7, —S(═O)(═NR7)R8, —N═S(═O)(R8)R7;
R2 represents an aryl group or heteroaryl group
which is substituted, one or more times, identically or differently, with a substituent selected from:
R9—, R9—(C1-C6-alkyl)-, R9—(CH2)n(CHOH)(CH2)m—, R9—(C1-C6-alkoxy)-, R9—(CH2)n(CHOH)(CH2)p—O—, R9—(C1-C6-alkoxy-C1-C6-alkyl)-, R9—(C1-C6-alkoxy-C1-C6-alkyl)-O—, —O—(CH2)n—C(═O)NR9R7, R9—O—, —C(═O)R9, —C(═O)O—R9, —OC(═O)—R9, —N(H)C(═O)R9, —N(R7)C(═O)R9, —N(H)C(═O)NR9R7, —N(R7)C(═O)NR9R7, —NR9R7, —C(═O)N(H)R9, —C(═O)NR9R7, R9—S—, R9—S(═O)—, R9—S(═O)2—, —N(H)S(═O)R9, —N(R7)S(═O)R9, —S(═O)N(H)R9, —S(═O)NR9R7, —N(H)S(═O)2R9, —N(R7)S(═O)2R9, —S(═O)2N(H)R9, —S(═O)2NR9R7, —S(═O)(═NR9)R7, —S(═O)(═NR7)R9, —N═S(═O)(R9)R7;
and
which is optionally substituted, one or more times, identically or differently, with a substituent selected from:
halo-, hydroxyl-, cyano-, nitro-, C1-C6-alkyl-, halo-C1-C6-alkyl-, C1-C6-alkoxy-, halo-C1-C6-alkoxy-, hydroxy-C1-C6-alkyl-, C1-C6-alkoxy-C1-C6-alkyl-, halo-C1-C6-alkoxy-C1-C6-alkyl-, R8—(C1-C6-alkyl)-, R8—(CH2)n(CHOH)(CH2)m—, R8—(C1-C6-alkoxy)-, R8—(CH2)n(CHOH)(CH2)p—O—, R8—(C1-C6-alkoxy-C1-C6-alkyl)-, R8—(C1-C6-alkoxy-C1-C6-alkyl)-O—, O—(CH2)n—C(═O)NR8R7, R8—O—, —C(═O)R8, —C(═O)O—R8, —OC(═O)—R8, —N(H)C(═O)R8, —N(R7)C(═O)R8, —N(H)C(═O)NR8R7, —N(R7)C(═O)NR8R7, —NR8R7, —C(═O)N(H)R8, —C(═O)NR8R7, R8—S—, R8—S(═O)—, R8—S(═O)2—, —N(H)S(═O)R8, —N(R7)S(═O)R8, —S(═O)N(H)R8, —S(═O)NR8R7, —N(H)S(═O)2R8, —N(R7)S(═O)2R8, —S(═O)2N(H)R8, —S(═O)2NR8R7, —S(═O)(═NR8)R7, —S(═O)(═NR7)R8, —N═S(═O)(R8)R7;
R3 represents a hydrogen atom, a halogen atom, a hydroxy-, amino, cyano-, nitro-, C1-C4-alkyl-, halo-C1-C4-alkyl-, C1-C4-alkoxy-, halo-C1-C4-alkoxy-, hydroxy-C1-C4-alkyl-, C1-C4-alkoxy-C1-C4-alkyl-, halo-C1-C4-alkoxy-C1-C4-alkyl-, C2-C6-alkenyl-, C2-C6-alkynyl-, halo-C2-C6-alkenyl-, halo-C2-C6-alkynyl-, C3-C6-cycloalkyl-, or halo-C3-C6-cycloalkyl- group;
R4 represents a hydrogen atom, a halogen atom, a hydroxy-, amino, cyano-, nitro-, C1-C4-alkyl-, halo-C1-C4-alkyl-, C1-C4-alkoxy-, halo-C1-C4-alkoxy-, hydroxy-C1-C4-alkyl-, C1-C4-alkoxy-C1-C4-alkyl-, halo-C1-C4-alkoxy-C1-C4-alkyl-, C2-C6-alkenyl-, C2-C6-alkynyl-, halo-C2-C6-alkenyl-, halo-C2-C6-alkynyl-, C3-C6-cycloalkyl-, or halo-C3-C6-cycloalkyl- group;
R5 represents a hydrogen atom;
R6 represents a group selected from:
C3-C6-cycloalkyl-, 3- to 10-membered heterocycloalkyl-, aryl-, heteroaryl-, —(CH2)q—(C3-C6-cycloalkyl), —(CH2)q-(3- to 10-membered heterocycloalkyl), —(CH2)q-aryl, or —(CH2)q-heteroaryl;
said group being optionally substituted, one or more times, identically or differently, with a substituent selected from:
halo-, hydroxyl-, cyano-, nitro-, C1-C6-alkyl-, halo-C1-C6-alkyl-, C1-C6-alkoxy-, halo-C1-C6-alkoxy-, hydroxy-C1-C6-alkyl-, C1-C6-alkoxy-C1-C6-alkyl-, halo-C1-C6-alkoxy-C1-C6-alkyl-, R8—(C1-C6-alkyl)-, R8—(CH2)n(CHOH)(CH2)m—, R8—(C1-C6-alkoxy)-, R8—(CH2)n(CHOH)(CH2)p—O—, R8—(C1-C6-alkoxy-C1-C6-alkyl)-, R8—(C1-C6-alkoxy-C1-C6-alkyl)-O—, aryl-, R8—O—, —C(═O)R8, —C(═O)O—R8, —OC(═O)—R8, —N(H)C(═O)R8, —N(R7)C(═O)R8, —N(H)C(═O)NR8R7, —N(R7)C(═O)NR8R7, —NR8R7, —C(═O)N(H)R8, —C(═O)NR8R7, R8—S—, R8—S(═O)—, R8—S(═O)2—, —N(H)S(═O)R8, —N(R7)S(═O)R8, —S(═O)N(H)R8, —S(═O)NR8R7, —N(H)S(═O)2R8, —N(R7)S(═O)2R8, —S(═O)2N(H)R8, —S(═O)2NR8R7, —S(═O)(═NR8)R7, —S(═O)(═NR7)R8, —N═S(═O)(R8)R7;
R7 represents a hydrogen atom, a C1-C6-alkyl-, or C3-C6-cycloalkyl- group;
or
R6 and R7,
together with the nitrogen atom to which they are attached, represent a 3- to 10-membered heterocycloalkyl- group, which is optionally substituted, one or more times, identically or differently, with halogen, hydroxy, cyano-, nitro-, C1-C6-alkyl-, halo-C1-C6-alkyl-, C1-C6-alkoxy-, halo-C1-C6-alkoxy-, hydroxy-C1-C6-alkyl-, C1-C6-alkoxy-C1-C6-alkyl-, halo-C1-C6-alkoxy-C1-C6-alkyl-, C2-C6-alkenyl-, C2-C6-alkynyl- or C3-C6-cycloalkyl-;
R8 represents a hydrogen atom or a C1-C6-alkyl- group;
R9 represents a group selected from:
C7-C10-cycloalkyl-, 3- to 10-membered heterocycloalkyl-, aryl-, heteroaryl-;
said group being optionally substituted, one or more times, identically or differently, with a substituent selected from:
halo-, hydroxyl-, cyano-, nitro-, C1-C6-alkyl-, halo-C1-C6-alkyl-, C1-C6-alkoxy-, halo-C1-C6-alkoxy, hydroxy-C1-C6-alkyl-, C1-C6-alkoxy-C1-C6-alkyl-, halo-C1-C6-alkoxy-C1-C6-alkyl-, —(CH2)q—(C3-C6-cycloalkyl), R8—(CH2)n(CHOH)(CH2)m—, R8—(C1-C6-alkoxy)-, R8—(CH2)n(CHOH)(CH2)p—O—, R8—(C1-C6-alkoxy-C1-C6-alkyl)-, R8—(C1-C6-alkoxy-C1-C6-alkyl)-O—, aryl-, R8—O—, —C(═O)R8, —C(═O)O—R8, —OC(═O)—R8, —N(H)C(═O)R8, —N(R7)C(═O)R8, —N(H)C(═O)NR8R7, —N(R7)C(═O)NR8R7, —NR8R7, —C(═O)N(H)R8, —C(═O)NR8R7, R8—S—, R8—S(═O)—, R8—S(═O)2—, —N(H)S(═O)R8, —N(R7)S(═O)R8, —S(═O)N(H)R8, —S(═O)NR8R7, —N(H)S(═O)2R8, —N(R7)S(═O)2R8, —S(═O)2N(H)R8, —S(═O)2NR8R7, —S(═O)(═NR8)R7, —S(═O)(═NR7)R8, —N═S(═O)(R8)R7;
or
R9 and R7,
together with the nitrogen atom to which they are attached, represent a 3- to 10-membered heterocycloalkyl- group, which is optionally substituted, one or more times, identically or differently, with halogen, hydroxy, cyano-, nitro-, C1-C6-alkyl-, halo-C1-C6-alkyl-, C1-C6-alkoxy-, halo-C1-C6-alkoxy-, hydroxy-C1-C6-alkyl-, C1-C6-alkoxy-C1-C6-alkyl-, halo-C1-C6-alkoxy-C1-C6-alkyl-, C2-C6-alkenyl-, C2-C6-alkynyl-, —C(═O)O—R8 or C3-C6-cycloalkyl-;
n, m, p
represent, independently from each other, an integer of 0, 1, 2, 3, 4, or 5;
q represents an integer of 0, 1, 2 or 3;
or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein:
R1 represents an aryl or heteroaryl group
which is substituted, one or more times, identically or differently, with a substituent selected from:
R6—(CH2)n(CHOH)(CH2)m—, R6—(C1-C6-alkoxy)-, R6—(CH2)n(CHOH)(CH2)p—O—, R6—(C1-C6-alkoxy-C1-C6-alkyl)-, R6—(C1-C6-alkoxy-C1-C6-alkyl)-O—, R6—O—, —C(═O)R6, —C(═O)O—R6, —OC(═O)—R6, —N(H)C(═O)R6, —N(R7)C(═O)R6, —N(H)C(═O)NR6R7, —N(R7)C(═O)NR6R7, —NR6R7, —C(═O)N(H)R6, —C(═O)NR6R7, R6—S—, R6—S(═O)—, R6—S(═O)2—, —N(H)S(═O)R6, —N(R7)S(═O)R6, —S(═O)N(H)R6, —S(═O)NR6R7, —N(H)S(═O)2R6, —N(R7)S(═O)2R6, —S(═O)2N(H)R6, —S(═O)2NR6R7, —S(═O)(═NR6)R7, —S(═O)(═NR7)R6, —N═S(═O)(R6)R7;
and
which is optionally substituted, one or more times, identically or differently, with a substituent Rxy selected from:
halo-, hydroxyl-, cyano-, C1-C6-alkyl-, halo-C1-C6-alkyl-, C1-C6-alkoxy-, halo-C1-C6-alkoxy-, hydroxy-C1-C6-alkyl-, —N(H)C(═O)R8, —N(R7)C(═O)R8, —C(═O)N(H)R8, —C(═O)NR8R7;
or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.

### Claim 3 (depends on 1)

The compound according to claim 1, wherein:
R2 represents an aryl group or heteroaryl group
which is substituted, one or more times, identically or differently, with a substituent selected from:
R9—, R9—(C1-C6-alkyl)-, R9—(C1-C6-alkoxy)-, R9—O—, —C(═O)R9, —N(H)C(═O)R9, —N(R7)C(═O)R9, —N(H)C(═O)NR9R7, —N(R7)C(═O)NR9R7, —NR9R7, —C(═O)N(H)R9, —C(═O)NR9R7, R9—S(═O)—, R9—S(═O)2—, —N(H)S(═O)2R9, —N(R7)S(═O)2R9, —S(═O)2N(H)R9, —S(═O)2NR9R7, —S(═O)(═NR9)R7, —S(═O)(═NR7)R9;
and
which is optionally substituted, one or more times, identically or differently, with a substituent selected from:
halo-, hydroxyl-, cyano-, C1-C6-alkyl-, halo-C1-C6-alkyl-, C1-C6-alkoxy-, halo-C1-C6-alkoxy-, —C(═O)R8, —C(═O)O—R8, —OC(═O)—R8, —N(H)C(═O)R8, —N(R7)C(═O)R8, —N(H)C(═O)NR8R7, —N(R7)C(═O)NR8R7, —NR8R7, —C(═O)N(H)R8, —C(═O)NR8R7, R8—S—, R8—S(═O)—, R8—S(═O)2—, —N(R7)S(═O)2R8, —S(═O)2N(H)R8, —S(═O)2NR8R7, —S(═O)(═NR8)R7, —S(═O)(═NR7)R8;
or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.

### Claim 4 (depends on 1)

The compound according to claim 1, wherein:
R3 represents a hydrogen atom, a halogen atom, a hydroxy-, amino, cyano-, C1-C4-alkyl-, hydroxy-C1-C4-alkyl or C2-C6-alkynyl- group;
R4 represents a hydrogen atom, a halogen atom, a hydroxy-, amino, cyano-, C1-C4-alkyl-, hydroxy-C1-C4-alkyl or C2-C6-alkynyl- group;
R6 represents a group selected from:
(CH2)q—(C3-C6-cycloalkyl), —(CH2)q-(3- to 10-membered heterocycloalkyl), —(CH2)q-aryl, or —(CH2)q-heteroaryl;
said group being optionally substituted, one or more times, identically or differently, with a substituent selected from:
halo-, C1-C6-alkyl-, halo-C1-C6-alkyl-, C1-C6-alkoxy-, halo-C1-C6-alkoxy-,
or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.

### Claim 5 (depends on 1)

The compound according to claim 1, wherein:
R1 represents an aryl group
which is substituted, one or more times, identically or differently, with a substituent selected from:
—C(═O)R6, —C(═O)O—R6, —OC(═O)—R6, —N(H)C(═O)R6, —C(═O)N(H)R6, —C(═O)NR6R7, R6—S(═O)—, R6—S(═O)2—, —N(H)S(═O)2R6, —S(═O)2N(H)R6, —S(═O)(═NR6)R7, —S(═O)(═NR7)R6;
and
which is optionally substituted, one or more times, identically or differently, with a substituent Rxy selected from:
halo-, hydroxyl-, cyano-, C1-C6-alkyl-, C1-C6-alkoxy-, hydroxy-C1-C6-alkyl-, —N(H)C(═O)R8, —N(R7)C(═O)R8, —C(═O)N(H)R8, —C(═O)NR8R7;
R2 represents an aryl group or heteroaryl group
which is substituted, one or more times, identically or differently, with a substituent selected from:
R9—, R9—(C1-C6-alkyl)-, R9—(C1-C6-alkoxy)-, —C(═O)R9, —N(H)C(═O)R9, —N(R7)C(═O)R9, —N(H)C(═O)NR9R7, —N(R7)C(═O)NR9R7, —NR9R7, —C(═O)N(H)R9, —C(═O)NR9R7, R9—S(═O)—, R9—S(═O)2—, —N(H)S(═O)2R9, —N(R7)S(═O)2R9, —S(═O)2N(H)R9, —S(═O)2NR9R7, —S(═O)(═NR9)R7, —S(═O)(═NR7)R9;
and
which is optionally substituted, one or more times, identically or differently, with a substituent selected from:
halo-, hydroxyl-, cyano-, C1-C6-alkyl-, halo-C1-C6-alkyl-, C1-C6-alkoxy-, halo-C1-C6-alkoxy-, —C(═O)R8, —C(═O)O—R8, —OC(═O)—R8, —N(H)C(═O)R8, —N(R7)C(═O)R8, —N(H)C(═O)NR8R7, —N(R7)C(═O)NR8R7, —NR8R7, —C(═O)N(H)R8, —C(═O)NR8R7, R8—S(═O)—, R8—S(═O)2—, —N(R7)S(═O)2R8, —S(═O)2N(H)R8, —S(═O)2NR8R7, —S(═O)(═NR8)R7, —S(═O)(═NR7)R8;
R3 represents a hydrogen atom, a halogen atom, a hydroxy-, amino, cyano-, C1-C4-alkyl-, hydroxy-C1-C4-alkyl or C2-C6-alkynyl- group;
R4 represents a hydrogen atom, a halogen atom, a hydroxy-, amino, cyano-, C1-C4-alkyl-, hydroxy-C1-C4-alkyl or C2-C6-alkynyl- group;
R5 represents a hydrogen atom;
R6 represents a group selected from:
C3-C6-cycloalkyl-, —(CH2)q—(C3-C6-cycloalkyl), —(CH2)q-(3- to 10-membered heterocycloalkyl), —(CH2)q-aryl, or —(CH2)q-heteroaryl;
said group being optionally substituted, one or more times, identically or differently, with a substituent selected from:
halo-, C1-C6-alkyl-, halo-C1-C6-alkyl-, C1-C6-alkoxy-, halo-C1-C6-alkoxy-;
R7 represents a hydrogen atom or a C1-C6-alkyl- group;
or
R6 and R7,
together with the nitrogen atom to which they are attached, represent a 3- to 10-membered heterocycloalkyl- group, which is optionally substituted, one or more times, identically or differently, with halogen, hydroxy, cyano-, C1-C6-alkyl-, halo-C1-C6-alkyl-, C1-C6-alkoxy-, halo-C1-C6-alkoxy- or C3-C6-cycloalkyl-;
R8 represents a hydrogen atom or a C1-C6-alkyl- group;
R9 represents a group selected from:
C7-C10-cycloalkyl-, 3- to 10-membered heterocycloalkyl-, heteroaryl-;
said group being optionally substituted, one or more times, identically or differently, with a substituent selected from:
halo-, hydroxyl-, cyano-, C1-C6-alkyl-, halo-C1-C6-alkyl-, C1-C6-alkoxy-, halo-C1-C6-alkoxy-, hydroxy-C1-C6-alkyl-, —(CH2)q—(C3-C6-cycloalkyl), —C(═O)R8, —C(═O)O—R8, —N(H)C(═O)R8, —N(H)C(═O)NR8R7, —N(R7)C(═O)NR8R7, —NR8R7, —C(═O)N(H)R8, —C(═O)NR8R7, R8—S(═O)— or R8—S(═O)2—;
or
R9 and R7,
together with the nitrogen atom to which they are attached, represent a 3- to 10-membered heterocycloalkyl- group, which is optionally substituted, one or more times, identically or differently, with halogen, hydroxy, cyano-, C1-C6-alkyl-, halo-C1-C6-alkyl-, C1-C6-alkoxy-, halo-C1-C6-alkoxy-, —C(═O)O—R8 or C3-C6-cycloalkyl;
q represents an integer of 0, 1, 2 or 3;
or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.

### Claim 6 (depends on 1)

The compound according to claim 1, wherein:
R1 represents a phenyl group
which is substituted, one or more times, identically or differently, with a substituent selected from:
—N(H)C(═O)R6 or —C(═O)N(H)R6;
and
which is optionally substituted, one time with a substituent Rxy selected from:
halo-, cyano-, C1-C6-alkyl-, C1-C6-alkoxy-;
R2 represents a phenyl or pyridyl group
which is substituted, one or more times, identically or differently, with a substituent selected from:
R9—, —C(═O)R9, —N(H)C(═O)R9, —N(R7)C(═O)R9, —N(H)C(═O)NR9R7, —N(R7)C(═O)NR9R7, —NR9R7, —C(═O)N(H)R9 or —C(═O)NR9R7;
and
which is optionally substituted, one or more times, identically or differently, with a substituent selected from:
halo-, hydroxyl-, C1-C6-alkyl-, halo-C1-C6-alkyl-, C1-C6-alkoxy-, halo-C1-C6-alkoxy-;
R3 represents a hydrogen atom;
R4 represents a hydrogen atom;
R5 represents a hydrogen atom;
R6 represents a group selected from:
C3-C6-cycloalkyl-, —(CH2)q—(C3-C6-cycloalkyl) or —(CH2)q-aryl;
said group being optionally substituted, one or more times, identically or differently, with a substituent selected from:
halo-;
R7 represents a hydrogen atom;
R8 represents a hydrogen atom or a C1-C6-alkyl- group;
R9 represents a group selected from:
C7-C10-cycloalkyl-, 3- to 10-membered heterocycloalkyl-;
said group being optionally substituted, one or more times, identically or differently, with a substituent selected from:
halo-, hydroxyl-, C1-C6-alkyl-, halo-C1-C6-alkyl-, C1-C6-alkoxy-, halo-C1-C6-alkoxy-, hydroxy-C1-C6-alkyl-, —(CH2)q—(C3-C6-cycloalkyl), —C(═O)R8, —C(═O)O—R8;
or
R9 and R7,
together with the nitrogen atom to which they are attached, represent a 3- to 10-membered heterocycloalkyl- group, which is optionally substituted, one or more times, identically or differently, with halogen, hydroxy, C1-C6-alkyl-, halo-C1-C6-alkyl-, C1-C6-alkoxy-, halo-C1-C6-alkoxy-, —C(═O)O—R8 or C3-C6-cycloalkyl-;
q represents an integer of 1 or 2;
or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.

### Claim 7 (depends on 1)

The compound according to claim 1, which is selected from the group consisting of:
2-cyclopropyl-N-[4-(2-{[2-methoxy-4-(morpholin-4-ylcarbonyl)phenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)phenyl]acetamide,
2-cyclopropyl-N-[4-(2-{[2-ethoxy-4-(morpholin-4-ylcarbonyl)phenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)phenyl]acetamide,
2-cyclopropyl-N-[4-(2-{[2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)phenyl]acetamide trifluoroacetate,
2-(4-fluorophenyl)-N-[4-(2-{[2-methoxy-4-(morpholin-4-ylcarbonyl)phenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)phenyl]acetamide,
N-[4-(2-{[2-ethoxy-4-(morpholin-4-ylcarbonyl)phenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)phenyl]-2-(4-fluorophenyl)acetamide,
N-[4-(2-{[4-(4,4-dimethyl-4,5-dihydro-1,3-oxazol-2-yl)-2-methoxyphenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)phenyl]-2-(4-fluorophenyl)acetamide,
2-(4-fluorophenyl)-N-{4-[2-({2-methoxy-4-[(4-methylpiperazin-1-yl)carbonyl]phenyl}amino)[,2]triazolo[1,5-a]pyridin-6-yl]phenyl}acetamide,
tert-butyl 4-(3-ethoxy-4-{[6-(4-{[(4-fluorophenyl)acetyl]amino}phenyl)[,2]triazolo[1,5-a]pyridin-2-yl]amino}benzoyl)piperazine-1-carboxylate,
N-[4-(2-{[2-ethoxy-4-(piperazin-1-ylcarbonyl)phenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)phenyl]-2-(4-fluorophenyl)acetamide,
N-(4-{2-[(4-{[4-(cyclopropylmethyl)piperazin-1-yl]carbonyl}-2-ethoxyphenyl)amino][,2]triazolo[1,5-a]pyridin-6-yl}phenyl)-2-(4-fluorophenyl)acetamide,
2-(4-fluorophenyl)-N-[4-(2-{[2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)phenyl]acetamide trifluoroacetate,
2-(4-fluorophenyl)-N-[4-(2-{[4-(morpholin-4-ylcarbonyl)-2-(2,2,2-trifluoroethoxy)phenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)phenyl]acetamide,
N-(cyclopropylmethyl)-4-(2-{[2-methoxy-4-(morpholin-4-ylcarbonyl)phenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)benzamide,
N-(cyclopropylmethyl)-4-(2-{[2-ethoxy-4-(morpholin-4-ylcarbonyl)phenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)benzamide,
N-(cyclopropylmethyl)-4-(2-{[4-(4,4-dimethyl-4,5-dihydro-1,3-oxazol-2-yl)-2-methoxyphenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)benzamide,
4-[(6-{4-[(cyclopropylmethyl)carbamoyl]phenyl}[,2]triazolo[1,5-a]pyridin-2-yl)amino]-3-ethoxy-N-(1-methylpiperidin-4-yl)benzamide,
N-(cyclopropylmethyl)-4-(2-{[2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)benzamide trifluoroacetate,
N-(cyclopropylmethyl)-4-(2-{[4-(morpholin-4-ylcarbonyl)-2-(2,2,2-trifluoroethoxy)phenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)benzamide,
N-(4-Fluorbenzyl)-4-(2-{[2-methoxy-4-(morpholin-4-ylcarbonyl)phenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)benzamid,
4-(2-{[2-Ethoxy-4-(morpholin-4-ylcarbonyl)phenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)-N-(4-fluorbenzyl)benzamid,
2-(4-fluorophenyl)-N-[4-(2-{[4-(morpholin-4-ylcarbonyl)-2-(trifluoromethoxy)phenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)phenyl]acetamide,
2-(4-fluorophenyl)-N-[4-(2-{[2-methoxy-4-(2-oxo-1,3-oxazolidin-3-yl)phenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)phenyl]acetamide,
N-[4-(2-{[2-ethoxy-4-(2-oxo-1,3-oxazolidin-3-yl)phenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)phenyl]-2-(4-fluorophenyl)acetamide,
2-(4-fluorophenyl)-N-[4-(2-{[4-methyl-6-(2-oxo-1,3-oxazolidin-3-yl)pyridin-3-yl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)phenyl]acetamide,
N-[4-(2-{[4-(4,5-dihydro-1,3-oxazol-2-yl)-2-methoxyphenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)phenyl]-2-(4-fluorophenyl)acetamide,
N-[4-(2-{[4-(4,5-dihydro-1,3-oxazol-2-yl)-2-methylphenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)phenyl]-2-(4-fluorophenyl)acetamide,
2-(4-fluorophenyl)-N-{4-[2-({2-methoxy-4-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-ylcarbonyl]phenyl}amino)[,2]triazolo[1,5-a]pyridin-6-yl]phenyl}acetamide,
2-(4-fluorophenyl)-N-[4-(2-{[2-methoxy-4-(2-oxa-6-azaspiro[3.3]hept-6-ylcarbonyl)phenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)phenyl]acetamide,
N-{4-[2-({4-[(1,1-dioxidothiomorpholin-4-yl)carbonyl]-2-methoxyphenyl}amino)[,2]triazolo[1,5-a]pyridin-6-yl]phenyl}-2-(4-fluorophenyl)acetamide,
2-(4-fluorophenyl)-N-{4-[2-({4-[(3-hydroxyazetidin-1-yl)carbonyl]-2-methoxyphenyl}amino)[,2]triazolo[1,5-a]pyridin-6-yl]phenyl}acetamide,
2-(4-fluorophenyl)-N-{4-[2-({4-[(4-hydroxypiperidin-1-yl)carbonyl]-2-methoxyphenyl}amino)[,2]triazolo[1,5-a]pyridin-6-yl]phenyl}acetamide,
4-{[6-(4-{[(4-fluorophenyl)acetyl]amino}phenyl)[,2]triazolo[1,5-a]pyridin-2-yl]amino}-3-methoxy-N-(oxetan-3-yl)benzamide,
N-[4-(2-{[4-(azetidin-1-ylcarbonyl)-2-methoxyphenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)phenyl]-2-(4-fluorophenyl)acetamide,
N-[4-(2-{[2-ethoxy-4-(2-oxa-6-azaspiro[3.3]hept-6-ylcarbonyl)phenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)phenyl]-2-(4-fluorophenyl)acetamide,
N-{4-[2-({2-ethoxy-4-[(3-hydroxyazetidin-1-yl)carbonyl]phenyl}amino)[,2]triazolo[1,5-a]pyridin-6-yl]phenyl}-2-(4-fluorophenyl)acetamide,
3-ethoxy-4-{[6-(4-{[(4-fluorophenyl)acetyl]amino}phenyl)[,2]triazolo[1,5-a]pyridin-2-yl]amino}-N-(1-methylpiperidin-4-yl)benzamide,
2-(4-fluorophenyl)-N-[4-(2-{[4-(2-oxa-6-azaspiro[3.3]hept-6-ylcarbonyl)-2-(2,2,2-trifluoroethoxy)phenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)phenyl]acetamide,
2-(4-fluorophenyl)-N-{4-[2-({4-[(3-hydroxyazetidin-1-yl)carbonyl]-2-(2,2,2-trifluoroethoxy)phenyl}amino)[,2]triazolo[1,5-a]pyridin-6-yl]phenyl}acetamide,
2-(4-fluorophenyl)-N-[4-(2-{[2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)phenyl]acetamide,
2-(4-fluorophenyl)-N-[4-(2-{[4-(morpholin-4-ylcarbonyl)phenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)phenyl]acetamide,
N-[4-(2-{[2-(2-fluoroethoxy)-4-(2-oxa-6-azaspiro[3.3]hept-6-ylcarbonyl)phenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)phenyl]-2-(4-fluorophenyl)acetamide,
N-[4-(2-{[2-(2,2-difluoroethoxy)-4-(morpholin-4-ylcarbonyl)phenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)phenyl]-2-(4-fluorophenyl)acetamide,
2-(4-fluorophenyl)-N-[4-(2-{[4-(morpholin-4-ylcarbonyl)-2-(trifluoromethyl)phenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)phenyl]acetamide,
2-(4-fluorophenyl)-N-[4-(2-{[2-methoxy-4-(morpholin-4-ylmethyl)phenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)phenyl]acetamide,
N-{4-[2-({2-ethoxy-4-[(1-methylpiperidin-4-yl)oxy]phenyl}amino)[,2]triazolo[1,5-a]pyridin-6-yl]phenyl}-2-(4-fluorophenyl)acetamide,
2-(4-fluorophenyl)-N-{4-[2-({2-methoxy-4-[(1-methylpiperidin-4-yl)oxy]phenyl}amino)[,2]triazolo[1,5-a]pyridin-6-yl]phenyl}acetamide,
2-(4-fluorophenyl)-N-{4-[2-({4-[(1-methylpiperidin-4-yl)oxy]-2-(methylsulfanyl)phenyl}amino)[,2]triazolo[1,5-a]pyridin-6-yl]phenyl}acetamide,
2-(4-fluorophenyl)-N-[4-(2-{[2-methoxy-4-(morpholin-4-ylsulfonyl)phenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)phenyl]acetamide,
2-(4-fluorophenyl)-N-[4-(2-{[2-methyl-4-(2-oxa-6-azaspiro[3.3]hept-6-ylcarbonyl)phenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)phenyl]acetamide,
2-(4-fluorophenyl)-N-[4-(2-{[2-methyl-4-(morpholin-4-ylcarbonyl)phenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)phenyl]acetamide,
2-(4-fluorophenyl)-N-[4-(2-{[4-(2-oxa-6-azaspiro[3.3]hept-6-ylcarbonyl)-2-(trifluoromethoxy)phenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)phenyl]acetamide,
2-(4-fluorophenyl)-N-[4-(2-{[2-methoxy-5-(morpholin-4-ylcarbonyl)phenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)phenyl]acetamide,
2-(4-fluorophenyl)-N-[4-(2-{[2-methyl-6-(morpholin-4-yl)pyridin-3-yl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)phenyl]acetamide,
2-(4-fluorophenyl)-N-[4-(2-{[2-methyl-6-(pyrrolidin-1-yl)pyridin-3-yl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)phenyl]acetamide,
N-{4-[2-({4-[(3-fluoroazetidin-1-yl)carbonyl]-2-methoxyphenyl}amino)[,2]triazolo[1,5-a]pyridin-6-yl]phenyl}-2-(4-fluorophenyl)acetamide,
N-(cyclopropylmethyl)-4-(2-{[2-methoxy-4-(2-oxa-6-azaspiro[3.3]hept-6-ylcarbonyl)phenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)benzamide,
N-(4-fluorobenzyl)-4-(2-{[2-methoxy-4-(2-oxo-1,3-oxazolidin-3-yl)phenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)benzamide,
4-(2-{[2-ethoxy-4-(2-oxo-1,3-oxazolidin-3-yl)phenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)-N-(4-fluorobenzyl)benzamide,
4-(2-{[4-(4,5-dihydro-1,3-oxazol-2-yl)-2-methoxyphenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)-N-(4-fluorobenzyl)benzamide,
N-(4-fluorobenzyl)-4-[2-({2-methoxy-4-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-ylcarbonyl]phenyl}amino)[,2]triazolo[1,5-a]pyridin-6-yl]benzamide,
N-(4-fluorobenzyl)-4-(2-{[2-methoxy-4-(2-oxa-6-azaspiro[3.3]hept-6-ylcarbonyl)phenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)benzamide,
N-(4-fluorobenzyl)-4-[2-({4-[(3-hydroxyazetidin-1-yl)carbonyl]-2-methoxyphenyl}amino)[,2]triazolo[1,5-a]pyridin-6-yl]benzamide,
4-[2-({4-[(1,1-dioxidothiomorpholin-4-yl)carbonyl]-2-methoxyphenyl}amino)[,2]triazolo[1,5-a]pyridin-6-yl]-N-(4-fluorobenzyl)benzamide,
N-(4-fluorobenzyl)-4-[2-({4-[(4-hydroxypiperidin-1-yl)carbonyl]-2-methoxyphenyl}amino)[,2]triazolo[1,5-a]pyridin-6-yl]benzamide,
4-[(6-{4-[(4-fluorobenzyl)carbamoyl]phenyl}[,2]triazolo[1,5-a]pyridin-2-yl)amino]-3-methoxy-N-(oxetan-3-yl)benzamide,
4-(2-{[2-ethoxy-4-(2-oxa-6-azaspiro[3.3]hept-6-ylcarbonyl)phenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)-N-(4-fluorobenzyl)benzamide,
4-[2-({4-[(4-acetylpiperazin-1-yl)carbonyl]-2-ethoxyphenyl}amino)[,2]triazolo[1,5-a]pyridin-6-yl]-N-(4-fluorobenzyl)benzamide,
4-[2-({2-ethoxy-4-[(3-hydroxyazetidin-1-yl)carbonyl]phenyl}amino)[,2]triazolo[1,5-a]pyridin-6-yl]-N-(4-fluorobenzyl)benzamide,
N-(4-fluorobenzyl)-4-(2-{[4-(2-oxa-6-azaspiro[3.3]hept-6-ylcarbonyl)-2-(2,2,2-trifluoroethoxy)phenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)benzamide,
N-(4-fluorobenzyl)-4-[2-({4-[(3-hydroxyazetidin-1-yl)carbonyl]-2-(2,2,2-trifluoroethoxy)phenyl}amino)[,2]triazolo[1,5-a]pyridin-6-yl]benzamide,
N-(4-fluorobenzyl)-4-(2-{[4-(morpholin-4-ylcarbonyl)-2-(2,2,2-trifluoroethoxy)phenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)benzamide,
N-(4-fluorobenzyl)-4-(2-{[2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)benzamide,
4-(2-{[4-(4-tert-butylpiperazin-1-yl)-2-methoxyphenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)-N-(4-fluorobenzyl)benzamide,
N-(4-fluorobenzyl)-4-(2-{[2-fluoro-4-(2-oxa-6-azaspiro[3.3]hept-6-ylcarbonyl)phenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)benzamide,
N-(4-fluorobenzyl)-4-(2-{[2-fluoro-4-(morpholin-4-ylcarbonyl)phenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)benzamide,
4-(2-{[2-(2,2-difluoroethoxy)-4-(morpholin-4-ylcarbonyl)phenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)-N-(4-fluorobenzyl)benzamide,
N-(4-fluorobenzyl)-4-(2-{[4-(morpholin-4-ylcarbonyl)-2-(trifluoromethyl)phenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)benzamide,
N-(4-fluorobenzyl)-4-[2-({2-methoxy-4-[(4-methylpiperazin-1-yl)methyl]phenyl}amino)[,2]triazolo[1,5-a]pyridin-6-yl]benzamide,
N-(4-fluorobenzyl)-4-(2-{[2-methoxy-4-(morpholin-4-ylmethyl)phenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)benzamide,
N-(4-fluorobenzyl)-4-[2-({2-methoxy-4-[(1-methylpiperidin-4-yl)oxy]phenyl}amino)[,2]triazolo[1,5-a]pyridin-6-yl]benzamide,
N-(4-fluorobenzyl)-4-[2-({4-[(1-methylpiperidin-4-yl)oxy]-2-(methylsulfanyl)phenyl}amino)[,2]triazolo[1,5-a]pyridin-6-yl]benzamide,
N-(4-fluorobenzyl)-4-(2-{[2-methyl-4-(2-oxa-6-azaspiro[3.3]hept-6-ylcarbonyl)phenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)benzamide,
N-(4-fluorobenzyl)-4-(2-{[2-methyl-4-(morpholin-4-ylcarbonyl)phenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)benzamide,
N-(4-fluorobenzyl)-4-(2-{[4-(2-oxa-6-azaspiro[3.3]hept-6-ylcarbonyl)-2-(trifluoromethoxy)phenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)benzamide,
N-(4-fluorobenzyl)-4-(2-{[4-(morpholin-4-ylcarbonyl)-2-(trifluoromethoxy)phenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)benzamide,
N-(4-fluorobenzyl)-4-(2-{[2-methoxy-5-(morpholin-4-ylcarbonyl)phenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)benzamide,
N-(4-fluorobenzyl)-4-(2-{[2-methyl-6-(morpholin-4-yl)pyridin-3-yl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)benzamide,
N-(4-fluorobenzyl)-4-(2-{[2-methyl-6-(pyrrolidin-1-yl)pyridin-3-yl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)benzamide,
4-[2-({4-[(3-fluoroazetidin-1-yl)carbonyl]-2-methoxyphenyl}amino)[,2]triazolo[1,5-a]pyridin-6-yl]-N-(4-fluorobenzyl)benzamide,
N-(4-chlorobenzyl)-4-(2-{[2-methoxy-4-(morpholin-4-ylcarbonyl)phenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)benzamide,
4-(2-{[2-methoxy-4-(morpholin-4-ylcarbonyl)phenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)-N-(4-methylbenzyl)benzamide,
2-fluoro-N-(4-fluorobenzyl)-4-(2-{[2-methoxy-4-(morpholin-4-ylcarbonyl)phenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)benzamide,
2-fluoro-N-(4-fluorobenzyl)-4-(2-{[2-methoxy-4-(morpholin-4-ylmethyl)phenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)benzamide,
N-(4-fluorobenzyl)-4-(2-{[2-methoxy-4-(morpholin-4-ylcarbonyl)phenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)-2-methylbenzamide,
N-(4-fluorobenzyl)-4-(2-{[2-methoxy-4-(2-oxo-1,3-oxazolidin-3-yl)phenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)-2-methylbenzamide,
2-chloro-N-(4-fluorobenzyl)-4-(2-{[2-methoxy-4-(morpholin-4-ylcarbonyl)phenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)benzamide,
N-(4-fluorobenzyl)-2-methoxy-4-(2-{[2-methoxy-4-(morpholin-4-ylcarbonyl)phenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)benzamide,
N-[2-fluoro-4-(2-{[2-methoxy-4-(morpholin-4-ylcarbonyl)phenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)phenyl]-2-(4-fluorophenyl)acetamide,
2-(4-fluorophenyl)-N-[5-(2-{[2-methoxy-4-(morpholin-4-ylcarbonyl)phenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)pyridin-2-yl]acetamide,
N-[5-(2-{[2-ethoxy-4-(morpholin-4-ylcarbonyl)phenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)pyridin-2-yl]-2-(4-fluorophenyl)acetamide,
N-(2,4-difluorobenzyl)-4-(2-{[2-methoxy-4-(2-oxo-1,3-oxazolidin-3-yl)phenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)-2-methylbenzamide,
N-(4-fluorobenzyl)-5-(2-{[2-methoxy-4-(2-oxa-6-azaspiro[3.3]hept-6-ylcarbonyl)phenyl]amino}[,2]triazolo[1,5-a]pyridin-6-yl)pyridine-2-carboxamide,
or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.

### Claim 8 (depends on 1)

A method of preparing a compound of general formula (I) according to claim 1, in which method an intermediate compound of general formula (5):
in which R1, R3, R4, and R5 are as defined for the compound of general formula (I) in claim 1,
is allowed to react with a compound of general formula (5a):
R2—Y (5a)
in which R2 is as defined for the compound of general formula (I) in claim 1 and Y represents a leaving group, thus providing a compound of general formula (I):
in which R1, R2, R3, R4, and R5 are as defined for the compound of general formula (I) in claim 1.

### Claim 9

(canceled)

### Claim 10 (depends on 1)

A pharmaceutical composition comprising a compound of general formula (I) according to claim 1, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, or a mixture of same, and a pharmaceutically acceptable diluent or carrier.

### Claim 11 (depends on 1)

A pharmaceutical combination comprising:
one or more compounds of general formula (I) according to claim 1, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, or a mixture of same;
and
one or more agents selected from: a taxane; an epothilone; Mitoxantrone; Predinisolone; Dexamethasone; Estramustin; Vinblastin; Vincristin; Doxorubicin; Adriamycin; Idarubicin; Daunorubicin; Bleomycin; Etoposide; Cyclophosphamide; Ifosfamide; Procarbazine; Melphalan; 5-Fluorouracil; Capecitabine; Fludarabine; Cytarabine; Ara-C; 2-Chloro-2″-deoxyadenosine; Thioguanine; an anti-androgen; Bortezomib; a platinum derivative; Chlorambucil; Methotrexate; and Rituximab.

### Claim 12

(canceled)

### Claim 13

(canceled)

### Claim 14 (depends on 1)

A method of the prophylaxis or treatment of a disease of uncontrolled cell growth, proliferation and/or survival, an inappropriate cellular immune response, or an inappropriate cellular inflammatory response mediated by Mps-1 comprising administering to a patient in need thereof an effective amount of a compound of general formula (I) according to claim 1, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, or a mixture of same.

### Claim 15 (depends on 1)

A compound of general formula (5):
in which R1, R3, R4, and R5 are as defined for the compound of general formula (I) in claim 1.

### Claim 16 (depends on 1)

A compound of general formula (7)
in which R2, R3, R4, and R5 are as defined for the compound of general formula (I) in claim 1, and R1a is an aryl or heteroaryl group to which an —NH2 substituent or a —COOH substituent is bound, and to which one or more Rxy substituents are optionally bound.

### Claim 17 (depends on 1)

A compound of general formula (4)
in which R2, R3, R4, and R5 are as defined for the compound of general formula (I) in claim 1, and Y represents a leaving group.

### Claim 18 (depends on 11)

The pharmaceutical combination according to claim 11, in which the taxane is selected from Docetaxel and Paclitaxel.

### Claim 19 (depends on 11)

The pharmaceutical combination according to claim 11, in which the epothilone is selected from Ixabepilone, Patupilone, and Sagopilone.

### Claim 20 (depends on 11)

The pharmaceutical combination according to claim 11, in which the anti-androgen is selected from Flutamide, Cyproterone acetate, and Bicalutamide.

### Claim 21 (depends on 11)

The pharmaceutical combination according to claim 11, in which the a platinum derivative is selected from Cisplatin and Carboplatin.

### Claim 22 (depends on 14)

The method according to claim 14, in which the disease of uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune response, or inappropriate cellular inflammatory response is selected from a haemotological tumour, a solid tumour and/or metastases thereof, leukaemias and myelodysplastic syndrome, malignant lymphomas, head and neck tumours, brain tumours and brain metastases, tumours of the thorax, non-small cell and small cell lung tumours, gastrointestinal tumours, endocrine tumours, mammary and gynaecological tumours, urological tumours, renal, bladder and prostate tumours, skin tumours, and sarcomas, and/or metastases thereof.